CML, Chronic Phase Clinical Trial
Official title:
A Double-blind , Randomized, Multicenter, Phase 4 Study to Evaluate Efficacy and Safety of Oral Flumatinib 400mg Versus 600mg in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
It's a double-blind , randomized ,multi-center study. The purpose of this study is to explore the efficacy and safety of flumatinib 400mg once daily (QD) versus 600mg QD as the first line therapy in patients with chronic myleiod leukemia(CML) in chronic phase(CP).
This is a dose-optimization study of flumatinib in adult patient with newly diagnosed CML-CP. The objective of this study is to compare the efficacy and safety of flumatinib 400mg QD with that of 600mg QD. Eligible patients are randomized in a 1:1 ratio to receive either fluamtinib 400mg QD or flumatinib 600mg QD. Randomization is stratified based on Sokal risk score (<0.8,0.8~1.2,>1.2). Patients will discontinue study therapy due to treatment failure, disease progression or intolerance to study medication or due to investigator's or participant's decision. The primary efficacy endpoint is the rate of early molecular response , as measured by RQ-PCR at 3 months. Hematologic response, molecular response and cytogenetic response will be assessed at baseline and a certain frequency after treatment, until study completion. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06409936 -
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
|
Phase 2 | |
| Not yet recruiting |
NCT06121765 -
Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI
|
||
| Not yet recruiting |
NCT06423911 -
A Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With CML
|
Phase 3 | |
| Recruiting |
NCT03459534 -
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
|
Phase 3 | |
| Completed |
NCT03885830 -
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
|
||
| Completed |
NCT04883125 -
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment
|
Phase 2 | |
| Recruiting |
NCT02949570 -
Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study
|
Phase 2 | |
| Not yet recruiting |
NCT05367765 -
A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
|
Phase 4 | |
| Recruiting |
NCT05367700 -
A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.
|
Phase 1 |